Zevra Therapeutics Inc. (ZVRA)
ZVRA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1434647/000143464726000011/0001434647-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ZVRA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001434647 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $106.5M |
| Net income | $83.2M |
| Operating income | -$62.9M |
| Net margin | 78.2% |
| Operating margin | -59.1% |
| Revenue growth | +350.9% |
| Cash | $62.4M |
| Total assets | $284.7M |
| P/E (computed) | 6.6× |
| P/S (computed) | 5.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $122.1M cash; operating cash flow $9.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 59,504,621 (2026-10-30); 56,297,535 a year earlier; 36,218,164 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Orlando, Florida, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $2.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $37.8M | $19.2M | $10.0M | $122.1M | $0 | $147.8M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $39.7M | $8.8M | $17.0M | $145.3M | $0 | $136.1M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $36.2M | $37.9M | $6.1M | $95.6M | $0 | $122.3M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $34.1M | $12.2M | $5.5M | $62.4M | $61.9M | $106.5M | 10-K 2026-03-09 |
| Q3 2025 2025-09-30 | $26.1M | -$544K | $4.7M | $54.4M | $61.3M | $84.4M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $25.9M | $74.7M | -$3.6M | $47.7M | $60.7M | $62.0M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $20.4M | -$3.1M | -$8.2M | $37.3M | $60.1M | $40.6M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $12.0M | -$35.7M | -$16.3M | $33.8M | $59.5M | $23.6M | 10-K 2026-03-09 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-08-09 |
| Latest annual report | 10-K | 2026-03-09 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEF 14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 870 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -21.7% |
| 1 month | -12.6% |
| 3 months | -18.8% |
| Year to date | +1.3% |
| 1 year | -1.6% |
| From 52-week high | -38.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EVO | Evotec SE | $1.56 | -1.27% | $555.0M |
| HELP | Helus Pharma Inc. | $7.67 | -13.53% | $560.4M |
| WVE | Wave Life Sciences Inc. | $2.87 | -8.31% | $566.0M |
| INDP | Indaptus Therapeutics Inc. | $3.45 | +8.83% | $529.9M |
| ACRS | Aclaris Therapeutics Inc. | $3.60 | -8.04% | $571.8M |
| CBIO | Crescent Biopharma Inc. | $13.50 | -4.59% | $525.1M |
| CLYM | Climb Bio Inc. | $9.94 | -4.05% | $583.9M |
| AVBP | ArriVent BioPharma Inc. | $11.56 | -11.15% | $597.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier